Acute Pancreatitis (AP)MAPPNCT04214756
Methodist Acute Pancreatitis Protocol
An observational study of Acute Pancreatitis (AP), run by Methodist Health System at 1 site in United States.
Trial summary
The overall goal of this ongoing registry study is to optimize initial evaluation and treatment of patients with AP according to recommended guidelines, the Methodist Acute Pancreatitis Protocol (MAPP), which were implemented in January 2015. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Pancreatitis (AP)
- What is being tested?
- Acute Pancreatitis
- Type of treatment
- Surgery or procedure
- How many people
- 500 participants
- Where
- 1 siteUnited States
- Study dates
- 5 Apr 2014to Jun 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: All patients diagnosed with acute pancreatitis beginning August 2011 at MDMC, MCMC, MMMC, and MRMC will be included in the registry for analysis of baseline and clinical outcomes data and subsequently divided into two groups (i.e. those treated pre-MAPP and post-MAPP).
Who may be able to join
- Age ≥ 18 years
- Presented to ER with Acute severe pain for < 48 hours before presentation.
- Laboratory values of Lipase and/or amylase > 3X normal
Who cannot join
- History of recent penetrating or blunt abdominal trauma
- Patients transferred to MDMC for upper abdominal pain consistent with pancreatic etiology
Trial locations and contacts
1 site in 1 country.
About this study
The overall goal of this ongoing registry study is to optimize initial evaluation and treatment of patients with AP according to recommended guidelines, the Methodist Acute Pancreatitis Protocol (MAPP), which were implemented in January 2015.
Read the detailed description
1.1. Background
Acute pancreatitis (AP) represents a significant burden for patients, their caregivers, and our healthcare delivery systems. The most common discharge gastrointestinal diagnosis is AP and more than two billion dollars is spent annually for management thereof . Costs are certainly even higher as the incidence of AP has increased. Admit frequency for AP doubled in 15 years before 2002 such that more than 200,000 admissions were attributed to AP, and the trend toward increased admissions for AP has continued. Overall, about 20% of AP cases are severe and the risk for fatality attributed to severe AP is significant (> 25%). Classification of AP severity is defined into three groups: mild, moderately severe, and severe. These categories have been validated in that standard clinical outcomes correlate well with the severity of AP.
There are several principle gaps in knowledge with respect to AP. First, it remains challenging to initially predict the ultimate severity of acute pancreatitis . Some patients presenting with what is thought to be a mild attack of AP ultimately progress to having more severe disease. This is of utmost importance because outcomes of AP seem to be clearly related to very early diagnosis and appropriate initial management. For example, both morbidity and mortality for AP are closely related to persistent organ failure, which in theory might be prevented with very early appropriate management. It is also not clear if the existing data regarding prognostic scoring systems were influenced by early interventions. Secondly, we lack confirmatory data that following recommended guidelines for management of AP in fact results in improved clinical outcomes. It has been suggested that the care of AP patients has changed considerably during the last decade. One might assume that this change was in response to following one or all of several different guidelines produced by international societies. However, there is a paucity of outcomes data, particularly related to patients that have been cared for according to the recommended guidelines, and further investigation is warranted. Lastly, many AP studies include patients who had onset of symptoms more than several days prior to admission or transfer to a tertiary center; careful study is warranted in AP patients who present within one to two days of symptom onset.
The evaluation and treatment of all patients with AP according to specific guidelines embodies the principles of patient-centeredness research and improved clinical outcomes may also translate into better quality of life. Patients who suffer from severe AP that is complicated by pancreatic necrosis continue to have poor physical components of quality of life. However, the burden for patients with AP extends beyond the obvious clinical outcomes. Even as symptom scales from quality of life instruments improve following recovery, mental component scores remain significantly impaired.
1.2. AIMS/OBJECTIVES
Specific aims:
Aim 1: Compare the outcome of AP between the two groups. The total length of hospital stay (including ward stay and ICU stay) and the Discharge status (discharged or died) will be considered as the outcome of AP.
Aim 2: Compare the imaging study and hospital resource utilization (charges) between the two groups
Aim 3: Determine if the existing prognostic scoring systems are valid in this patient population when managed according the recommended guidelines.
1.3. HYPOTHESIS 1.4.1. Primary Hypothesis: The total length of hospital stay will be shorter for the group of patients treated after January 2015 (post-MAPP) than those treated before December 2014 (pre-MAPP). Additionally, more patients treated according to the guidelines will be discharged home (and not die in the hospital) as compared to the patients not treated according to the guidelines.
1.4.2. Secondary Hypothesis: There will be less utilization of imaging studies for patients treated according to the guidelines.
2.1. STUDY OBJECTIVES 2.1.1. Primary Objective Compare the total length of hospital stay (including ward stay and ICU stay) and the discharge status (discharged or died) between the pre- and post-MAPP AP patients.
2.1.2. Secondary Objectives
- Compare the imaging study and hospital resource utilization (charges) between the pre- and post-MAPP AP patients.
- Determine if the existing prognostic scoring systems are valid in the AP patient population when managed according the recommended guidelines
- STUDY DESIGN The proposed ongoing registry study will follow the cohort study design where baseline patient data and clinical outcomes data will be collected retrospectively. The registry will collect data on all AP patients since August 2011, and will continue until a sufficient number of cases are obtained to reach statistical significance. Retrospective data will be collected on patients diagnosed with AP based on two groups (those treated pre-MAPP and post-MAPP). Initial clinical criteria will be evaluated for the predictive value of AP severity in both groups.
- STUDY SETTING/LOCATION The study will be conducted with data from Methodist Dallas Medical Center (MDMC), Methodist Charlton Medical Center (MCMC), Methodist Mansfield Medical Center (MMMC) and Methodist Richardson Medical Center (MRMC).
- Conditions
- Acute Pancreatitis (AP)
- Being tested
- Acute Pancreatitis
- Medical subject headings
- Pancreatitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Acute PancreatitisProcedure or surgery
All patients diagnosed with acute pancreatitis beginning August 2011 at MDMC, MCMC, MMMC, and MRMC will be included in the registry for analysis of baseline and clinical outcomes data and subsequently divided into two groups (i.e. those treated pre-MAPP and post-MAPP).
| Study group | Role | What they receive |
|---|---|---|
| Patients treated pre-MAPP | The registry will collect data on all AP patients since August 2011, and will continue until a sufficient number of cases are obtained to reach statistical significance | |
| Patients treated post-MAPP | The registry will collect data on all AP patients since August 2011, and will continue until a sufficient number of cases are obtained to reach statistical significance Receives: Procedure: Acute Pancreatitis |
What is being measured
The primary outcome is the main question the study is designed to answer.
Length of Hospital Stay
Length of hospital stay will be calculated in days with a discrete variable as [(discharge date - Admission date)].
Measured: From April 2016 until Jun 2025 (anticipated study close)
Ward days
Length of ward days will be calculated in days with a discrete variable as [(discharge date from ward - Admission date to the ward)].
Measured: From April 2016 until Jun 2025 (anticipated study close)
ICU days
Length of ICU stay will be calculated in days with a discrete variable as [(discharge date from ICU - Admission date to the ICU)].
Measured: From April 2016 until Jun 2025 (anticipated study close)
Discharge status
will be recorded as a categorical variable indicating whether the discharge was to the home, SNF or rehab facility (1=Home; 2 = SNF; 3 = Rehab)
Measured: From April 2016 until Jun 2025 (anticipated study close)
Secondary outcomes (8)
CT scan
will be recorded as a binary variable indicating whether the CT scan was done in the ER (1 = Yes; 0 = No).
Measured: From April 2016 until Jun 2025 (anticipated study close)
Empiric antibiotics
will be recorded as a binary variable indicating whether antibiotics were used (1 = Yes; 0 = No).
Measured: From April 2016 until Jun 2025 (anticipated study close)
Harmless AP score (HAPS)
The Harmless Acute Pancreatitis Score is used to predicts within 30 minutes of admission patients whose acute pancreatitis will run a mild course. Scored from 0-4. A score of 0 is associated with the absence of pancreatic necrosis , and 4 with severe presence (Balthazar score, 0-4 points)
Measured: From April 2016 until Jun 2025 (anticipated study close)
bedside index for severity in AP (BISAP)
Predicts mortality risk in pancreatitis, and is scored from 0 to 5. Patients with a BISAP Score of 0 would have <1% risk of mortality, whereas a score of 5 would indicate a mortality rate of 22%.
Measured: From April 2016 until Jun 2025 (anticipated study close)
C reactive protein
C reactive protein levels produced in patient's liver would be evaluated
Measured: From April 2016 until Jun 2025 (anticipated study close)
Procalcitonin
Procalcitonin levels produced in patients will be evaluated
Measured: From April 2016 until Jun 2025 (anticipated study close)
organ dysfunction scores
organ dysfunction scores is scored from 0 to 5. If no organ dysfunction is present, the score is 0, rising to a maximum of 5.
Measured: From April 2016 until Jun 2025 (anticipated study close)
Severity of acute pancreatitis (AP)
Severity of AP will be measured by categorizing into mild, moderately severe and severe according to the revised Atlanta classification (RAC).(7, 27) Mild severity is defined as having no organ failure and no local (acute fluid collection, acute necrotic collection, pseudocyst, walled-off necrosis) or systemic (exacerbation of preexisting co- morbidities) complications. Moderately severe AP is defined as transient organ failure (<48 hours) and/or local/systemic complications without persistent organ failure. And severe AP is defined as persistent single or multiple organ failure (> 48 h) (1= Mild; 2= Moderate severity; 3 = Severe AP). (27)
Measured: From April 2016 until Jun 2025 (anticipated study close)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Jan 2020
- Study start5 Apr 2014
- Primary completion5 Apr 2026 (estimated)
- Study completionJun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Pancreatitis (AP)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Retrospective
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Methodist Health System
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Paul Tarnasky, MD, Principal investigator, The Methodist Hospital Research Institute
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04214756
- Sponsor's protocol ID
- 035.GID.2014.D
- Acronym
- MAPP
- Status last verified
- Mar 2026
- First submitted
- 12 Aug 2019
- Last updated
- 20 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Methodist Acute Pancreatitis Protocol
- ClinicalTrials.gov ID
- NCT04214756
- Acronym / sponsor ID
- MAPP / 035.GID.2014.D
- Conditions
- Acute Pancreatitis (AP)
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Methodist Health SystemUniversity, hospital or other
- Study start
- 5 Apr 2014 (actual)
- Primary completion
- 5 Apr 2026 (estimated)
- Study completion
- Jun 2026 (estimated)
- First posted
- 2 Jan 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The overall goal of this ongoing registry study is to optimize initial evaluation and treatment of patients with AP according to recommended guidelines, the Methodist Acute Pancreatitis Protocol (MAPP), which were implemented in January 2015.
Detailed description
1.1. Background
Acute pancreatitis (AP) represents a significant burden for patients, their caregivers, and our healthcare delivery systems. The most common discharge gastrointestinal diagnosis is AP and more than two billion dollars is spent annually for management thereof . Costs are certainly even higher as the incidence of AP has increased. Admit frequency for AP doubled in 15 years before 2002 such that more than 200,000 admissions were attributed to AP, and the trend toward increased admissions for AP has continued. Overall, about 20% of AP cases are severe and the risk for fatality attributed to severe AP is significant (> 25%). Classification of AP severity is defined into three groups: mild, moderately severe, and severe. These categories have been validated in that standard clinical outcomes correlate well with the severity of AP.
There are several principle gaps in knowledge with respect to AP. First, it remains challenging to initially predict the ultimate severity of acute pancreatitis . Some patients presenting with what is thought to be a mild attack of AP ultimately progress to having more severe disease. This is of utmost importance because outcomes of AP seem to be clearly related to very early diagnosis and appropriate initial management. For example, both morbidity and mortality for AP are closely related to persistent organ failure, which in theory might be prevented with very early appropriate management. It is also not clear if the existing data regarding prognostic scoring systems were influenced by early interventions. Secondly, we lack confirmatory data that following recommended guidelines for management of AP in fact results in improved clinical outcomes. It has been suggested that the care of AP patients has changed considerably during the last decade. One might assume that this change was in response to following one or all of several different guidelines produced by international societies. However, there is a paucity of outcomes data, particularly related to patients that have been cared for according to the recommended guidelines, and further investigation is warranted. Lastly, many AP studies include patients who had onset of symptoms more than several days prior to admission or transfer to a tertiary center; careful study is warranted in AP patients who present within one to two days of symptom onset.
The evaluation and treatment of all patients with AP according to specific guidelines embodies the principles of patient-centeredness research and improved clinical outcomes may also translate into better quality of life. Patients who suffer from severe AP that is complicated by pancreatic necrosis continue to have poor physical components of quality of life. However, the burden for patients with AP extends beyond the obvious clinical outcomes. Even as symptom scales from quality of life instruments improve following recovery, mental component scores remain significantly impaired.
1.2. AIMS/OBJECTIVES
Specific aims:
Aim 1: Compare the outcome of AP between the two groups. The total length of hospital stay (including ward stay and ICU stay) and the Discharge status (discharged or died) will be considered as the outcome of AP.
Aim 2: Compare the imaging study and hospital resource utilization (charges) between the two groups
Aim 3: Determine if the existing prognostic scoring systems are valid in this patient population when managed according the recommended guidelines.
1.3. HYPOTHESIS 1.4.1. Primary Hypothesis: The total length of hospital stay will be shorter for the group of patients treated after January 2015 (post-MAPP) than those treated before December 2014 (pre-MAPP). Additionally, more patients treated according to the guidelines will be discharged home (and not die in the hospital) as compared to the patients not treated according to the guidelines.
1.4.2. Secondary Hypothesis: There will be less utilization of imaging studies for patients treated according to the guidelines.
2.1. STUDY OBJECTIVES 2.1.1. Primary Objective Compare the total length of hospital stay (including ward stay and ICU stay) and the discharge status (discharged or died) between the pre- and post-MAPP AP patients.
2.1.2. Secondary Objectives
- Compare the imaging study and hospital resource utilization (charges) between the pre- and post-MAPP AP patients.
- Determine if the existing prognostic scoring systems are valid in the AP patient population when managed according the recommended guidelines
- STUDY DESIGN The proposed ongoing registry study will follow the cohort study design where baseline patient data and clinical outcomes data will be collected retrospectively. The registry will collect data on all AP patients since August 2011, and will continue until a sufficient number of cases are obtained to reach statistical significance. Retrospective data will be collected on patients diagnosed with AP based on two groups (those treated pre-MAPP and post-MAPP). Initial clinical criteria will be evaluated for the predictive value of AP severity in both groups.
- STUDY SETTING/LOCATION The study will be conducted with data from Methodist Dallas Medical Center (MDMC), Methodist Charlton Medical Center (MCMC), Methodist Mansfield Medical Center (MMMC) and Methodist Richardson Medical Center (MRMC).
Study design
- Observational model
- Case-control
- Time perspective
- Retrospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients treated pre-MAPP | – | –The registry will collect data on all AP patients since August 2011, and will continue until a sufficient number of cases are obtained to reach statistical significance |
| Patients treated post-MAPP | – | Procedure: Acute PancreatitisThe registry will collect data on all AP patients since August 2011, and will continue until a sufficient number of cases are obtained to reach statistical significance |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- All patients diagnosed with acute pancreatitis beginning August 2011 at MDMC, MCMC, MMMC, and MRMC will be included in the registry for analysis of baseline and clinical outcomes data and subsequently divided into two groups (i.e. those treated pre-MAPP and post-MAPP).
Key inclusion criteria (3 listed)
- Age ≥ 18 years
- Presented to ER with Acute severe pain for < 48 hours before presentation.
- Laboratory values of Lipase and/or amylase > 3X normal
Key exclusion criteria (2 listed)
- History of recent penetrating or blunt abdominal trauma
- Patients transferred to MDMC for upper abdominal pain consistent with pancreatic etiology
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Acute PancreatitisAll patients diagnosed with acute pancreatitis beginning August 2011 at MDMC, MCMC, MMMC, and MRMC will be included in the registry for analysis of baseline and clinical outcomes data and subsequently divided into two groups (i.e. those treated pre-MAPP and post-MAPP). | Procedure or surgery | Patients treated post-MAPP |
Primary outcome
Length of Hospital Stay
Time frame: From April 2016 until Jun 2025 (anticipated study close)
Length of hospital stay will be calculated in days with a discrete variable as [(discharge date - Admission date)].
Ward days
Time frame: From April 2016 until Jun 2025 (anticipated study close)
Length of ward days will be calculated in days with a discrete variable as [(discharge date from ward - Admission date to the ward)].
ICU days
Time frame: From April 2016 until Jun 2025 (anticipated study close)
Length of ICU stay will be calculated in days with a discrete variable as [(discharge date from ICU - Admission date to the ICU)].
Discharge status
Time frame: From April 2016 until Jun 2025 (anticipated study close)
will be recorded as a categorical variable indicating whether the discharge was to the home, SNF or rehab facility (1=Home; 2 = SNF; 3 = Rehab)
8 secondary outcomes
CT scan
Time frame: From April 2016 until Jun 2025 (anticipated study close)
Empiric antibiotics
Time frame: From April 2016 until Jun 2025 (anticipated study close)
Harmless AP score (HAPS)
Time frame: From April 2016 until Jun 2025 (anticipated study close)
bedside index for severity in AP (BISAP)
Time frame: From April 2016 until Jun 2025 (anticipated study close)
C reactive protein
Time frame: From April 2016 until Jun 2025 (anticipated study close)
Procalcitonin
Time frame: From April 2016 until Jun 2025 (anticipated study close)
organ dysfunction scores
Time frame: From April 2016 until Jun 2025 (anticipated study close)
Severity of acute pancreatitis (AP)
Time frame: From April 2016 until Jun 2025 (anticipated study close)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Acute Pancreatitis (AP)
Not yet recruiting
Cold Water Papillary Irrigation Plus Rectal NSAIDs vs Rectal NSAIDs Alone for Post-ERCP Pancreatitis (COLD)
Post ERCP Pancreatitis, Acute Pancreatitis (AP)
Not yet recruitingPhase 4
Varenicline for Smoking Cessation in Pancreatitis
Pancreatitis, Chronic Pancreatitis
RecruitingObservational study
ENDoscopic Assessment in Acute PANcreatitis Study (ENDOPAN Study)
Acute Pancreatitis (AP)
Not yet recruiting
A Trial of the Arctx Cool Catheter in Acute Pancreatitis
Acute Pancreatitis (AP)
Recruiting
Stroke Volume-based Fluid Resuscitation in AP
Acute Pancreatitis (AP)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Paul Tarnasky, MD principal investigator
The Methodist Hospital Research Institute
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Acute Pancreatitis (AP), run by Methodist Health System at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 20 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Length of Hospital Stay (time frame: From April 2016 until Jun 2025 (anticipated study close)). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Mar 2026; AzTrials last refreshed its copy on 27 Oct 2026.